Abstract:BACKGROUND: In a randomized trial, the early introduction of peanuts in infants at high risk for allergy was shown to prevent peanut allergy. In this follow-up study, we investigated whether the rate of peanut allergy remained low after 12 months of peanut avoidance among participants who had consumed peanuts during the primary trial (peanut-consumption group), as compared with those who had avoided peanuts (peanut-avoidance group).METHODS: At the end of the primary trial, we instructed all the participants to avoid peanuts for 12 months. The primary outcome was the percentage of participants with peanut allergy at the end of the 12-month period, when the participants were 72 months of age.RESULTS: We enrolled 556 of 628 eligible participants (88.5%) from the primary trial; 550 participants (98.9%) had complete primary-outcome data. The rate of adherence to avoidance in the follow-up study was high (90.4% in the peanut-avoidance group and 69.3% in the peanut-consumption group). Peanut allergy at 72 months was significantly more prevalent among participants in the peanut-avoidance group than among those in the peanut-consumption group (18.6% [52 of 280 participants] vs. 4.8% [13 of 270], P<0.001). Three new cases of allergy developed in each group, but after 12 months of avoidance there was no significant increase in the prevalence of allergy among participants in the consumption group (3.6% [10 of 274 participants] at 60 months and 4.8% [13 of 270] at 72 months, P=0.25). Fewer participants in the peanut-consumption group than in the peanut-avoidance group had high levels of Ara h2 (a component of peanut protein)-specific IgE and peanut-specific IgE; in addition, participants in the peanut-consumption group continued to have a higher level of peanut-specific IgG4 and a higher peanut-specific IgG4:IgE ratio.CONCLUSIONS: Among children at high risk for allergy in whom peanuts had been introduced in the first year of life and continued until 5 years of age, a 12-month period of peanut avoidance was not associated with an increase in the prevalence of peanut allergy. Longer-term effects are not known. (Funded by the National Institute of Allergy and Infectious Diseases and others; LEAP-On ClinicalTrials.gov number, NCT01366846.).

Peanut Immunotherapy Increases Allergic and Anaphylactic Reactions, Finds Review

Efficacy of Allergen-Specific Immunotherapy for Peanut Allergy: a Meta-Analysis of Randomized Controlled Trials.

From Skin to Solution: Exploring Epicutaneous Immunotherapy for Peanut Allergy—A Systematic Review and Meta-Analysis

Peanut immunotherapy provides long lasting suppression of allergy, finds study

The Risk Reduction of Accidental Exposure-Related Systemic Allergic Reactions Extrapolated Based on Food Challenge Data After 1 Year of Peanut Oral Immunotherapy

Peanut allergy: risk factors, immune mechanisms, and best practices for oral immunotherapy success

Weighing the benefits and risks of oral immunotherapy in clinical practice

Effect of Avoidance on Peanut Allergy after Early Peanut Consumption

Peanut Allergy in Children—Is Prevention Better than Cure?

Peanut allergy in toddlers

Optimising the management of peanut allergy by targeting immune plasticity

Role of dendritic cells in peanut allergy

Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy

Current state and advances in desensitization for peanut allergy in pediatric age

Exploratory immunogenicity outcomes of peanut oral immunotherapy: Findings from the PALISADE trial

Efficacy and safety of oral immunotherapy for peanut, cow's milk, and hen's egg allergy: A systematic review of randomized controlled trials

Enhanced Gut Microbiome Capacity for Amino Acid Metabolism is associated with Peanut Oral Immunotherapy Failure

International study of risk-mitigating factors and in-flight allergic reactions to peanut and tree nut

Is Component-Specific Antibody Testing Sufficient to Replace the Oral Food Challenge in the Diagnostics of Peanut-Sensitized Children? A Proof-of-Concept Study

Oral immunotherapy for food allergy in children: is it worth it?

The global burden of illness of peanut allergy: A comprehensive literature review